Dexmedetomidine Preconditioning Reduces Myocardial Ischemia-Reperfusion Injury in Rats by Inhibiting the PERK Pathway
Overview
Affiliations
Background: Ischemic heart disease has attracted much attention due to its high mortality rates, treatment costs and the increasing morbidity in the young population. Strategies for reperfusion have reduced mortality. However, reperfusion can lead to cardiomyocyte death and subsequent irreversible myocardial damage. At present, the timely and targeted treatment of ischemia-reperfusion (I/R) injury is often lacking.
Objectives: To evaluate if dexmedetomidine (DEX) has a protective effect in myocardiual I/R and explore the possible mechanism behind it.
Methods: Rat hearts were perfused with a Langendorff perfusion system, and randomly assigned to five groups: control group, perfused with Krebs-Henseleit (K-H) solution for 205 minutes without ischemia; and four test groups that underwent 40 minutes of global ischemia and 120 min of reperfusion. The DEX group, the yohimbine (YOH) group and the DEX + YOH group were perfused with DEX (10 nM), YOH (1 μM) or the combination of DEX and YOH prior to reperfusion, respectively. Cardiac hemodynamics, myocardial infarct size, and myocardial histology were evaluated. The expression of glucose-related protein 78 (GRP78), protein kinase R-like ER kinase (PERK), phosphorylated PERK, eukaryotic initiation factor 2α (eIF2α), phosphorylated eIF2α, activating transcription factor 4 (ATF4), and CCAAT/enhancer-binding protein homologous protein (CHOP) were assessed. P<0.05 was considered to indicate a statistically significant difference.
Results: DEX preconditioning improved the cardiac function of I/R hearts, reduced myocardial infarction, myocardial apoptosis, and the expression of GRP78, p-PERK, eIF2α, p-eIF2α, ATF4 and CHOP.
Conclusions: DEX pretreatment reduced myocardial I/R injury by suppressing apoptosis, which was induced by the PERK pathway.
Different types of cell death and their interactions in myocardial ischemia-reperfusion injury.
Du B, Fu Q, Yang Q, Yang Y, Li R, Yang X Cell Death Discov. 2025; 11(1):87.
PMID: 40044643 PMC: 11883039. DOI: 10.1038/s41420-025-02372-5.
Targeting ferroptosis as a promising therapeutic strategy to treat cardiomyopathy.
Sun H, Chen D, Xin W, Ren L, Li Q, Han X Front Pharmacol. 2023; 14:1146651.
PMID: 37138856 PMC: 10150641. DOI: 10.3389/fphar.2023.1146651.
Preconditioning in Ischemia-Reperfusion Lesion.
Gatto M, Mota G, Pagan L, Gomes M, Okoshi M Arq Bras Cardiol. 2022; 117(6):1145-1146.
PMID: 35613171 PMC: 8757153. DOI: 10.36660/abc.20210908.
Protective effects of dexmedetomidine in vital organ injury: crucial roles of autophagy.
Zhao S, Wu W, Lin X, Shen M, Yang Z, Yu S Cell Mol Biol Lett. 2022; 27(1):34.
PMID: 35508984 PMC: 9066865. DOI: 10.1186/s11658-022-00335-7.
The Year in Basic Research 2021: the Search for Translational Models.
Gatto M, Mota G, Okoshi M Arq Bras Cardiol. 2022; 118(4):667-668.
PMID: 35508043 PMC: 9007007. DOI: 10.36660/abc.20220186.